Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer : a Copenhagen Breast Cancer Genomics Study. / Jensen, M.-B.; Pedersen, C. B.; Misiakou, M.-A.; Talman, M- L. M.; Gibson, L.; Tange, U. B.; Kledal, H.; Vejborg, I.; Kroman, N.; Nielsen, F. C.; Ejlertsen, B.; Rossing, M.
In: npj Breast Cancer, Vol. 9, 47, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer
T2 - a Copenhagen Breast Cancer Genomics Study
AU - Jensen, M.-B.
AU - Pedersen, C. B.
AU - Misiakou, M.-A.
AU - Talman, M- L. M.
AU - Gibson, L.
AU - Tange, U. B.
AU - Kledal, H.
AU - Vejborg, I.
AU - Kroman, N.
AU - Nielsen, F. C.
AU - Ejlertsen, B.
AU - Rossing, M.
N1 - Publisher Copyright: © 2023, The Author(s).
PY - 2023
Y1 - 2023
N2 - Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) expression guide the use of neoadjuvant chemotherapy (NACT) in patients with early breast cancer. We evaluate the independent predictive value of adding a multigene profile (CIT256 and PAM50) to immunohistochemical (IHC) profile regarding pathological complete response (pCR) and conversion of positive to negative axillary lymph node status. The cohort includes 458 patients who had genomic profiling performed as standard of care. Using logistic regression, higher pCR and node conversion rates among patients with Non-luminal subtypes are shown, and importantly the predictive value is independent of IHC profile. In patients with ER-positive and HER2-negative breast cancer an odds ratio of 9.78 (95% CI 2.60;36.8), P < 0.001 is found for pCR among CIT256 Non-luminal vs. Luminal subtypes. The results suggest a role for integrated use of up-front multigene subtyping for selection of a neoadjuvant approach in ER-positive HER2-negative breast cancer.
AB - Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) expression guide the use of neoadjuvant chemotherapy (NACT) in patients with early breast cancer. We evaluate the independent predictive value of adding a multigene profile (CIT256 and PAM50) to immunohistochemical (IHC) profile regarding pathological complete response (pCR) and conversion of positive to negative axillary lymph node status. The cohort includes 458 patients who had genomic profiling performed as standard of care. Using logistic regression, higher pCR and node conversion rates among patients with Non-luminal subtypes are shown, and importantly the predictive value is independent of IHC profile. In patients with ER-positive and HER2-negative breast cancer an odds ratio of 9.78 (95% CI 2.60;36.8), P < 0.001 is found for pCR among CIT256 Non-luminal vs. Luminal subtypes. The results suggest a role for integrated use of up-front multigene subtyping for selection of a neoadjuvant approach in ER-positive HER2-negative breast cancer.
U2 - 10.1038/s41523-023-00551-0
DO - 10.1038/s41523-023-00551-0
M3 - Journal article
C2 - 37258527
AN - SCOPUS:85160930575
VL - 9
JO - npj Breast Cancer
JF - npj Breast Cancer
SN - 2374-4677
M1 - 47
ER -
ID: 367796401